Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001558370-21-007261
Filing Date
2021-05-14
Accepted
2021-05-14 16:05:28
Documents
35
Period of Report
2021-03-31

Document Format Files

Seq Description Document Type Size
1 6-K evax-20210331x6k.htm 6-K 17840
2 EX-99.1 evax-20210331ex99190818d.htm EX-99.1 393542
3 EX-99.2 evax-20210331ex992ec1aa2.htm EX-99.2 122091
4 GRAPHIC evax-20210331ex992ec1aa2001.jpg GRAPHIC 40689
  Complete submission text file 0001558370-21-007261.txt   1862711

Data Files

Seq Description Document Type Size
5 EX-101.INS evax-20210331.xml EX-101.INS 244598
6 EX-101.SCH evax-20210331.xsd EX-101.SCH 22673
7 EX-101.CAL evax-20210331_cal.xml EX-101.CAL 30255
8 EX-101.DEF evax-20210331_def.xml EX-101.DEF 45957
9 EX-101.LAB evax-20210331_lab.xml EX-101.LAB 169172
10 EX-101.PRE evax-20210331_pre.xml EX-101.PRE 123938
Mailing Address BREDGADE 34E COPENHAGEN K G7 1260
Business Address BREDGADE 34E COPENHAGEN K G7 1260 4531262615
Evaxion Biotech A/S (Filer) CIK: 0001828253 (see all company filings)

EIN.: 000000000 | State of Incorp.: G7 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-39950 | Film No.: 21924517
SIC: 2836 Biological Products, (No Diagnostic Substances)